Abstract
No public abstract is available from the verified source records.
Chee Khoon Lee, Danka S. Zebic, Rachel L. O’Connell, Yeh C. Lee, Katherine E. Francis, Jeffrey C. Goh, Sally Baron-Hay, Lawrence Kasherman, Ratnesh Srivastav, Christopher Steer, Tarek Meniawy, Sandy Simon, Deepa Mathur, Leanna Cheung, Margaret Wall, Clare L Scott, Alison Davis, Anna De Fazio, Sonia Yip, Michael Friedlander
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Epithelial ovarian cancer
2026
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2023.07.011 · 2023
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
10.1136/ijgc-2021-003142 · 2022
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the Aurelia open-label randomized phase III trial
10.1200/jco.2013.51.4489 · 2014
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
10.1016/s0140-6736(25)01040-2 · 2025
Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer
10.1056/nejmoa2309169 · 2023
Pembrolizumab VS placebo plus paclitaxel ± bevacizumab for platinum-resistant recurrent ovarian cancer: results from the PHASE 3 ENGOT-OV65/KEYNOTE-B96 study
10.1016/j.ijgc.2025.102732 · 2025
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
10.1016/s1470-2045(13)70253-5 · 2013
Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study
10.1080/0284186x.2018.1546061 · 2019
Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature
10.1093/oncolo/oyae093 · 2024
NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer
2026
Paragon (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression
10.3802/jgo.2019.30.e86 · 2019
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
10.1038/bjc.2016.435 · 2017
Cyclin D as a therapeutic target in cancer
10.1038/nrc3090 · 2011
The Strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies
10.1016/j.trecan.2016.11.006 · 2017
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer
10.1158/1078-0432.ccr-10-2307 · 2011
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
10.1002/cjp2.109 · 2018
Overall survival with ribociclib plus letrozole in advanced breast cancer
10.1056/nejmoa2114663 · 2022
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
10.1016/s1470-2045(18)30292-4 · 2018
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
10.1007/s11136-017-1729-8 · 2018
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer
10.1016/j.ygyno.2024.02.025 · 2024
A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018)
10.1016/j.ygyno.2025.05.022 · 2025
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
10.1136/esmoopen-2020-000926 · 2020
Phase II trial of ribociclib plus letrozole in women with recurrent low-grade serous carcinoma of the ovary, Fallopian tube, or peritoneum: a GOG partners trial (GOG 3026)
10.1200/jco-25-01348 · 2026
Integrated genomic analyses of ovarian carcinoma
10.1038/nature10166 · 2011
Whole–genome characterization of chemoresistant ovarian cancer
10.1038/nature14410 · 2015
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: an Ovarian Tumor Tissue Analysis consortium study
10.1002/cncr.34582 · 2023
Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication
10.1016/j.cell.2022.12.036 · 2023
Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC)
10.1200/jco.2025.43.16_suppl.5514 · 2025
Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers
10.18632/oncotarget.15858 · 2017
No additional external references are available.